We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$999M
AUM Growth
+$357M
Cap. Flow
+$419M
Cap. Flow %
41.94%
Top 10 Hldgs %
54.5%
Holding
94
New
23
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$20.4M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$20M
3
KYNB
Kyntra Bio
KYNB
+$19.3M
4
NRIX icon
Nurix Therapeutics
NRIX
+$14.5M
5
ORGO icon
Organogenesis Holdings
ORGO
+$14.4M

Top Sells

Rank Stock Value
1
FLXN
Flexion Therapeutics, Inc.
FLXN
+$12.7M
2
NEO icon
NeoGenomics
NEO
+$9.19M
3
CDNA icon
CareDx
CDNA
+$8.03M
4
HOWL icon
Werewolf Therapeutics
HOWL
+$7.53M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.49M

Sector Composition

Rank Sector Weight
1 Healthcare 70.82%
2 Financials 0.64%
3 Consumer Staples 0%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$145M 14.48%
+1,292,000
New +$156M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$79.8B
$113M 11.32%
+508,500
New +$115M
LNTH icon
3
Lantheus
LNTH
$6.82B
$51M 5.1%
1,764,627
+534,800
+43% +$14.2M
EPIX
4
DELISTED
ESSA Pharma
EPIX
$50.1M 5.01%
3,525,457
+657,434
+23% +$7.32M
BCAB icon
5
BioAtla
BCAB
$5.59M
$49.4M 4.94%
50,308
– –
UTHR icon
6
United Therapeutics
UTHR
$26.3B
$35.5M 3.55%
164,300
+62,500
+61% +$12.3M
AZN icon
7
AstraZeneca
AZN
$263B
$27.9M 2.79%
239,298
+79,600
+50% +$9.37M
SRDX
8
DELISTED
Surmodics
SRDX
$25.7M 2.57%
532,757
+151,235
+40% +$7.62M
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$372M
$23.8M 2.38%
318,275
+135,875
+74% +$10.7M
THER
10
DELISTED
THERATECHNOLOGIES INC COM
THER
$23.3M 2.33%
7,692,082
+79,699
+1% +$241K
NPCE icon
11
Neuropace
NPCE
$505M
$23.3M 2.33%
2,309,003
+638,867
+38% +$8.3M
KYNB
12
Kyntra Bio
KYNB
$28.5M
$21.9M 2.19%
+62,020
New +$19.3M
NRIX icon
13
Nurix Therapeutics
NRIX
$2.43B
$21.5M 2.15%
743,238
+479,338
+182% +$14.5M
NTRA icon
14
Natera
NTRA
$37.5B
$21.3M 2.13%
227,599
+88,610
+64% +$9.2M
IRMD icon
15
iRadimed
IRMD
$1.21B
$20.8M 2.08%
450,030
-649
-0.1% -$26.2K
SNN icon
16
Smith & Nephew
SNN
$12.9B
$20.5M 2.06%
+593,200
New +$20.4M
DICE
17
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$20.5M 2.05%
810,940
-68,963
-8% -$2.02M
APEN
18
DELISTED
Apollo Endosurgery, Inc.
APEN
$19.3M 1.94%
+2,295,100
New +$20M
FOCL
19
EDAP TMS S.A.
FOCL
$226M
$18.9M 1.89%
3,148,609
+192,242
+7% +$1.11M
ORGO icon
20
Organogenesis Holdings
ORGO
$308M
$18.5M 1.85%
1,999,087
+1,359,200
+212% +$14.4M
CCCC icon
21
C4 Therapeutics
CCCC
$376M
$18.1M 1.81%
561,122
-189,511
-25% -$7.49M
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.9M 1.79%
1,068,376
-24,644
-2% -$404K
KRYS icon
23
Krystal Biotech
KRYS
$9.88B
$16M 1.6%
228,437
+102,908
+82% +$5.99M
CVS icon
24
CVS Health
CVS
$137B
$14.2M 1.43%
+138,000
New +$12.8M
ANGO icon
25
AngioDynamics
ANGO
$562M
$14.2M 1.42%
515,450
+272,925
+113% +$7.53M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Soleus Capital Management held 94 positions worth $999M, up 56% from $642M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Soleus Capital Management deployed $419M of net new capital in Q4 2021, opening 23 new positions and adding to 23 existing holdings. Its largest new stake was Smith & Nephew: 593,200 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 92% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Werewolf Therapeutics, an estimated $7.53M trimmed.

  • Soleus Capital Management's largest Q4 2021 buy was Smith & Nephew: 593,200 shares worth $20.5M.
  • Soleus Capital Management added most to Nurix Therapeutics in Q4 2021, an estimated $14.5M increase.
  • Soleus Capital Management's biggest Q4 2021 reduction was Werewolf Therapeutics, cutting an estimated $7.53M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q4 2021, selling an estimated $12.7M.
  • Soleus Capital Management's ten largest holdings make up 54% of its $999M portfolio in Q4 2021.
  • Soleus Capital Management opened 23 new positions and closed 26 in Q4 2021.
  • Soleus Capital Management's portfolio value rose 56% quarter-over-quarter to $999M.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.